Rhenman & Partners Asset Management Ab Increased Portola Pharmaceuticals Inc (NASDAQ:PTLA) Stake by $10.08 Million

October 13, 2017 - By Migdalia James

Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It fall, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Great West Life Assurance Can invested in 5,798 shares. Quantitative Invest Management Limited Liability Company holds 53,600 shares. Credit Suisse Ag reported 107,945 shares stake. Rhumbline Advisers holds 0.01% or 57,479 shares. Fortaleza Asset Management Incorporated has invested 0.31% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). 1,265 were reported by Victory Cap Mngmt. Massachusetts-based Fmr Limited Liability Corporation has invested 0.03% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). New York-based Bankshares Of Ny Mellon has invested 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Tortoise Invest Mgmt Ltd Liability Corp holds 0% or 164 shares in its portfolio. Deerfield Mgmt invested in 419,000 shares. Jpmorgan Chase & reported 718,158 shares stake. Art Advisors Limited Liability Corporation invested in 57,500 shares. Bnp Paribas Arbitrage has invested 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Weiss Multi reported 10,500 shares. Smith Asset Management Limited Partnership, Texas-based fund reported 9,460 shares.

Since May 31, 2017, it had 1 insider buy, and 1 sale for $54.68 million activity. The insider Maxwell (Mauritius) Pte Ltd sold $58.48 million.

Rhenman & Partners Asset Management Ab increased its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 168.4% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 186,595 shares as the company’s stock rose 22.73% with the market. The institutional investor held 297,400 shares of the health care company at the end of 2017Q3, valued at $16.07 million, up from 110,805 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $3.30 billion market cap company. The stock decreased 3.51% or $1.87 during the last trading session, reaching $51.42. About 735,146 shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since October 14, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $68.17’s average target is 32.57% above currents $51.42 stock price. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Buy” rating by Oppenheimer on Monday, June 26. Morgan Stanley maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Friday, August 19. Morgan Stanley has “Overweight” rating and $28 target. Citigroup downgraded the shares of PTLA in report on Friday, August 19 to “Neutral” rating. The firm has “Buy” rating given on Monday, August 28 by Oppenheimer. The firm earned “Buy” rating on Wednesday, August 5 by Cowen & Co. Goldman Sachs downgraded the shares of PTLA in report on Monday, March 28 to “Neutral” rating. The rating was maintained by Oppenheimer on Sunday, July 23 with “Buy”. Morgan Stanley maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Monday, June 26. Morgan Stanley has “Buy” rating and $7000 target. Citigroup maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Monday, June 26. Citigroup has “Buy” rating and $7800 target. Goldman Sachs initiated Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Friday, December 18 with “Buy” rating.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

More recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Expect A Slow Bleed With Portola Pharma” on September 22, 2017. Also Globenewswire.com published the news titled: “Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise …” on October 11, 2017. Seekingalpha.com‘s news article titled: “Portola – A High-Risk, High-Return Investment Opportunity” with publication date: September 21, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.